Cargando…

The Editors Respond Regarding the Shortcomings in Reported Research on Value-Based Insurance Design

Detalles Bibliográficos
Autores principales:	Fairman, Kathleen A., Curtiss, Frederic R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2008
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438234/ http://dx.doi.org/10.18553/jmcp.2008.14.3.326

Ejemplares similares

Making the World Safe for Evidence-Based Policy: Let's Slay the Biases in Research on Value-Based Insurance Design
por: Fairman, Kathleen A., et al.
Publicado: (2008)

The Editors Respond
por: Curtiss, Frederic R.
Publicado: (2010)

Still Looking for Health Outcomes in All the Wrong Places? Misinterpreted Observational Evidence, Medication Adherence Promotion, and Value-Based Insurance Design
por: Fairman, Kathleen A., et al.
Publicado: (2009)

How Do Seniors Respond to 100% Cost-Sharing for Prescription Drugs? Quality of the Evidence Underlying Opinions About the Medicare Part D Coverage Gap
por: Fairman, Kathleen A., et al.
Publicado: (2011)

Call for Letters Regarding Disclosure of Potential Conflicts of Interest in the Managed Care Literature -- Too Much, Too Little, or Just About Right?
por: Fairman, Kathleen A., et al.
Publicado: (2009)

The Editors Respond: The Diminishing Role of Montelukast in Asthma Therapy
por: Crownover, Brian K., et al.
Publicado: (2006)

Tough Questions About the Value of Statin Therapy for Primary Prevention: Did JUPITER Miss the Moon?
por: Curtiss, Frederic R., et al.
Publicado: (2010)

Rethinking the Whodunnit Approach to Assessing the Quality of Health Care Research -- A Call to Focus on the Evidence in Evidence-Based Practice
por: Fairman, Kathleen A., et al.
Publicado: (2008)

Selling Real-World Health Care Research to Reluctant Buyers-Evidence-Based Education or Marketing a Defective Product?
por: Fairman, Kathleen A., et al.
Publicado: (2009)

Call for Comparative Effectiveness Research: Lowering A1c with Sitagliptin, Saxagliptin, or Cinnamon
por: Fairman, Kathleen A., et al.
Publicado: (2009)

ADD or ADHD or What Exactly?--GIGO Part II and Other Lessons in Research with Administrative Claims
por: Curtiss, Frederic R., et al.
Publicado: (2007)

Shortcomings in addressing attacks on health care
por: Jaff, Dilshad
Publicado: (2018)

Shortcomings in Pharmacy Benefit Forecasting - Interferon Beta Products
por: Rich, Sheldon
Publicado: (2003)

Switching Antidepressant Drug Therapy Helps Some Patients Some of the Time--What TORDIA, STAR*D, and Observational Research Have Taught Us About Treatment-Resistant Depression
por: Curtiss, Frederic R., et al.
Publicado: (2008)

Hemicrania continua: major shortcomings in the new classification
por: Fredriksen, Torbjørn A, et al.
Publicado: (2014)

Non-Standardized Terminology in Healthcare: Shortcomings and Subsequent Rectifications [Letter]
por: Kumar, Harit, et al.
Publicado: (2022)

Municipal Shortcomings
Publicado: (1904)

Professional Shortcomings
por: Foster, J. H.
Publicado: (1871)

Public Psychological Health in COVID-19 Outbreak: Actions and Shortcomings
por: Jaberi, Azita
Publicado: (2020)

Letter to the Editor Regarding “Research Equity in Otolaryngology–Head and Neck Surgery”
por: Mbougo Djoutsop, Olga, et al.
Publicado: (2021)

Letter to the Editor Regarding “Research Progress on Serratus Anterior Plane Block in Breast Surgeries”
por: Sethuraman, Raghuraman M.
Publicado: (2023)

Shortcomings in risk projection.
por: Harley, N H
Publicado: (1989)

The Shortcomings of Plenum Ventilation
Publicado: (1906)

Diabetes Drug Therapy -- First Do No Harm
por: Curtiss, Frederic R., et al.
Publicado: (2008)

It's Only a Pharmacoeconomic Model--Believe It or Not
por: Fairman, Kathleen A., et al.
Publicado: (2008)

Sugarcane Ratooning Ability: Research Status, Shortcomings, and Prospects
por: Xu, Fu, et al.
Publicado: (2021)

Protecting Patients from Adverse Drug Events: Propoxyphene, PIMs, and Drugs to Avoid in Older Adults
por: Curtiss, Frederic R., et al.
Publicado: (2011)

Regulatory Actions on the Off-Label Use of Prescription Drugs: Ongoing Controversy and Contradiction in 2009 and 2010
por: Fairman, Kathleen A., et al.
Publicado: (2010)

Clinical Quality Indicators and Provider Financial Incentives: Does Money Matter?
por: Fairman, Kathleen A., et al.
Publicado: (2010)

Utilization Management Opportunities for Palivizumab for Prophylaxis of Respiratory Syncytial Virus Complications in Infants
por: Curtiss, Frederic R., et al.
Publicado: (2010)

Does Medicalization of Life Imperil Health? Expanding Indications for Diagnosis and Treatment of Chronic “Disease”
por: Fairman, Kathleen A., et al.
Publicado: (2011)

Managed Care and Health Care Reform: Everything Old Is New Again
por: Fairman, Kathleen A., et al.
Publicado: (2009)

What Do We Really Know About VBID? Quality of the Evidence and Ethical Considerations for Health Plan Sponsors
por: Fairman, Kathleen A., et al.
Publicado: (2011)

VBID, the PPACA, and FREEE Medications: Did Politics Trump the Evidence About Cost Sharing?
por: Fairman, Kathleen A., et al.
Publicado: (2012)

The Elephant in the Pharmacy: Patient Choice Is the Big Challenge That No One Talks About in Affordability of Prescription Drugs
por: Fairman, Kathleen A., et al.
Publicado: (2007)

What Should Be Done About Bias and Misconduct in Clinical Trials?
por: Fairman, Kathleen A., et al.
Publicado: (2009)

It Depends on What Mean Means: Averaging Versus Event Patterning in Analyses of Administrative Claims Data
por: Fairman, Kathleen A., et al.
Publicado: (2010)

Lessons Learned from Randomized Trials and Recent Experience with Health Information Technology: Promising Interventions Meet Real-World Patient Care
por: Fairman, Kathleen A., et al.
Publicado: (2010)

Letter to the editor: Regarding the editorial by Penttinen and Friede
por: Fry, Alicia M, et al.
Publicado: (2016)

Letter to Editor Regarding the OCEAN Study [Letter]
por: Yawn, Barbara P, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q4vsvqgcp6puhj2clvlt9cdoul